Scinai Immunotherapeutics ( NASDAQ: SCNI ) said it has received an additional Nasdaq Staff determination letter over non-compliance with the minimum shareholders' equity requirement. The company said one of the components of its plan to regain compliance could include the conversion of a part of the company's loan from the European Investment Bank into equity. More on Scinai Immunotherapeutics Seeking Alpha’s Quant Rating on Scinai Immunotherapeutics Financial information for Scinai Immunotherapeutics.
